Double Blind, Randomized Phase III Study to Evaluate the Immunogenicity and Safety of 'BR-TD-1001' Administered Intramuscularly in Healthy Children

Conditions:   Diphtheria;   Tetanus Interventions:   Biological: BR-TD-1001;   Biological: Td-pur inj Sponsor:   Boryung Biopharma Co., Ltd. Completed
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials